INNA ABLYAEVA: Open Payments
NPI 1134600133 · SCOTTSDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,207 in 88 payments from 22 companies in 2025. Trend: 2023 $1,117 · 2024 $2,049 · 2025 $2,207
Food & beverage: $2,207
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $322 |
| GlaxoSmithKline, LLC. | 16 | $268 |
| Grifols USA, LLC | 6 | $224 |
| Merck Sharp & Dohme LLC | 8 | $139 |
| Lilly USA, LLC | 3 | $136 |
| Actelion Pharmaceuticals US, Inc. | 4 | $127 |
| GENZYME CORPORATION | 4 | $113 |
| ViiV Healthcare Company | 3 | $113 |
| Viatris Specialty LLC | 4 | $104 |
| United Therapeutics Corporation | 6 | $103 |
Products named: TEZSPIRE, Prolastin-C Liquid, DUPIXENT, TRELEGY ELLIPTA, ZERBAXA, OPSUMIT, DOVATO, AIRSUPRA.
Industry payments across AZ — which companies pay providers there.
